Dr. Susan Todd Peeler offers comprehensive GYN care, including advanced gynecologic surgical options, for women of the Annapolis area.
Mercy's team of cancer doctors diagnose and treat melanoma, a very serious form of skin cancer.
Cardiologists at The Heart Center at Mercy treat patients with heart conditions including heart attack, heart murmur and heart disease.
Mercy offers emergency care on the Downtown Baltimore campus 24 hours a day, 7 days a week (410-332-9477) with access to a trained emergency medicine team, diagnostic services and consultations with specialists.
In case of an Emergency, Dial 911 and follow the instructions of the EMS (Emergency Medical Services) team.
Mercy Medical Center's downtown campus includes our Main Hospital - The Mary Catherine Bunting Center, McAuley Plaza and The Weinberg Center.
General visiting hours at Mercy are 11:00 am to 8:30 pm. Hours vary by floor, please check with the nursing staff or call 410-332-9555.
Currently Displaying: Active Clinical Trials
This is a research study comparing Atezolizumab (Anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple‑negative breast cancer. (Clinicaltrials.gov ID#: NCT03498716)
This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). This study will help to show whether weight loss programs should be a part of breast cancer treatment. (Clinicaltrials.gov ID#: NCT02750826)
This trial compares the efficacy and safety of elacestrant to the standard of care fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on at least one endocrine therapy. (ClinicalTrials.gov ID#: NCT03778931)
The purpose of this registry is to create a large-scale, population-based database. This database will match health information to genome information to look at the Agendia Breast Cancer suite and new gene associations. The Agendia Breast Cancer Suite includes MammaPrint® and BluePrint™, which are tests that help your doctor analyze and profile your breast cancer tumor. DiscoverPrint is for research purposes only. (Clinicaltrials.gov ID#: NCT03053193)
This is an open-label, randomized, multicenter Phase 3 study to compare the efficacy and safety of Sacituzumab Govitecan versus TPC in subjects with metastatic or locally recurrent inoperable HR+/HER2- MBC, after failure of at least 2, and no more than 4, prior chemotherapy regimens for metastatic disease. (Clinicaltrials.gov ID#: NCT03901339)
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (Clinicaltrials.gov ID#: NCT03701334).
This is a prospective observational study to estimate the incidence of febrile neutropenia among subjects with non-myeloid malignancies at high risk for febrile neutropenia and receiving Neulasta® (Pegfilgrastim) Onpro® kit or other physician choice options for prophylaxis of febrile neutropenia.
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Non Small Cell Lung Cancer, Ovarian Cancer or Breast Cancer. (Clinicaltrials.gov ID#: NCT03937154)
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects with Gastrointestinal or Colorectal Cancer. (Clinicaltrials.gov ID#: NCT03362177)
This is a phase III randomized trial evaluate the efficacy and safety of pembrolizumab for women with triple-negative breast cancer who have residual invasive cancer or positive lymph nodes after neoadjuvant chemotherapy. (Clinicaltrials.gov ID#: NCT02954874)
This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) or cannot be removed completely with surgery. (Clinicaltrials.gov ID#: NCT03975647)
Medical Oncology and Hematology at Mercy Medical Center in Baltimore, Maryland, provides diagnosis and treatment for a broad range of cancers including leukemia and lymphoma, neuroendocrine tumors, colorectal cancer, breast cancer, gynecologic cancers, prostate cancer and lung cancer. Experienced medical oncologists and hematologists offer expertise in cancer treatment through chemicals, biological products and immunotherapy, including chemotherapy, chemoembolization, biological and endocrine therapies and radiofrequency abalation.
Medical Oncology and Hematology is part of The Institute for Cancer Care at Mercy Medical Center.
Dr. M. Saad Khan is a medical oncologist and hematologist at Medical Oncology and Hematology at Mercy in Baltimore, a division of The Institute for Cancer Care at Mercy.